Index

Note: Page numbers of article titles are in **boldface** type.

A
Abscess(es), crypt, in dogs, treatment of, 394–395
Adherent and invasive *Escherichia coli* (AIEC), in Crohn disease, in Boxer dogs, 437–438
Adverse food reactions (AFRs)
  cutaneous, in dogs and cats, 366–368
  defined, 361
  in dogs and cats, 361–379
    clinical signs of, 366–369
    described, 361–362
    diagnostic approach to, 370–373
      cutaneous form, 370
      GI form, 371–373
    differential diagnosis of, 369
    epidemiology of, 365–366
    pathogenesis of, 362–365
      allergens in, 363–365
      GI mucosal barrier in, 362–363
      gluten-sensitive enteropathy in, 364–365
      oral tolerance in, 363
    prognosis of, 376
    treatment of, 373–376
      client education and compliance in, 375
      dietary elimination trial in, 373–374
      dietary provocation test in, 375–376
      hydrolyzed diets in, 374–375
      novel protein diets in, 374
      oral medications in, 375
AFRs. See Adverse food reactions (AFRs).
AIEC. See Adherent and invasive *Escherichia coli* (AIEC).
Alimentary lymphoma
  in cats, 419–432
    causes of, 419
    described, 419
    diagnosis of, 421–425
    pathogenesis of, 419
    patient history in, 420–421
    physical examination of, 420–421
    prognosis of, 425–429
    signalment of, 420–421
    treatment of, 425–429
  in dogs, 430
Allergen(s), in pathogenesis of AFRs in dogs and cats, 363–365

doi:10.1016/S0195-5616(11)00050-7
vetsmall.theclinics.com
0195-5616/11/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
Antibiotic(s), for ARD, 282–283
Antibiotic-responsive diarrhea (ARD)
  idiopathic, diagnosis of, 282
  in small animals, 273–286
  causes of, 278–279
  clinical features of, 273–274
  described, 278
  treatment of, 282–283
  antimicrobials in, 282–283
Antimicrobial(s). See Antibiotic(s).
Antimicrobial susceptibility testing, in granulomatous colitis diagnosis in Boxer dogs, 435–436
Archaea, in dogs and cats, 267–269
ARD. See Antibiotic-responsive diarrhea (ARD).

B
Bacteria
  IBD in dogs related to, 383–384
  in small intestine, numbers of, 274–277
  intestinal, of dogs and cats, 261–266. See also Intestinal bacteria, of dogs and cats.
Bacterial culture, in intestinal microbiome characterization, 261, 263
Bacterial enteritis, in dogs and cats, 287–309. See also specific organisms causing,
  e.g., Campylobacter spp., bacterial enteritis in dogs and cats due to.
Campylobacter spp. and
  Clostridium spp. and
    C. difficile, 291–294
    C. perfringens, 294–297
  diagnosis of, diagnostic panels in, 299–300
Salmonella spp. and, 297–299
Bacterial infections, diagnostic tests for, in dogs and cats, 316–317
Bacterial metabolism markers, in SIBO diagnosis, 282
Bile salts, unconjugated, in SIBO diagnosis, 280
Biopsy(ies), intestinal
  in IBD diagnosis in dogs, 386
  in PLE diagnosis in dogs, 407
Boxer dogs, granulomatous colitis in, 433–445. See also Granulomatous colitis, in Boxer dogs.
  Breath hydrogen, in SIBO diagnosis, 280

C
CAFRs. See Cutaneous adverse food reactions (CAFRs).
Calprotectin, in GI disease diagnosis, 322
Campylobacter spp.
  bacterial enteritis in dogs and cats due to, 287–291
    diagnosis of, 289
    molecular diagnostic testing in, 290
    treatment of, 290
    zoonotic implications, 290–291
  described, 287–289
  diagnostic tests for, in dogs and cats, 316–317
Cat(s)
AFRs in, 361–379. See also Adverse food reactions (AFRs), in dogs and cats.
alimentary lymphoma in, 419–432. See also Alimentary lymphoma, in cats.
bacterial enteritis in, 287–309. See also Bacterial enteritis, in dogs and cats.
CEs in, 311–328. See also Chronic enteropathy (CE), in dogs and cats.
intestinal microbiota of, 261–272. See also Intestinal microbiota, of dogs and cats.

CE. See Chronic enteropathy (CE).

Chronic enteropathy (CE)
diet-responsive, in dogs and cats
AFRs related to, 368–369
pathogenesis of, 365
in dogs and cats, 311–328
diagnosis of, 311–312
laboratory tests in assessment of, 312–318
bacterial infections, 316–317
calprotectin, 322
helminth detection, 312–313
histoplasma, 317
N-methylhistamine, 323
new tests, 322–323
pANCA, 322
protozoal infections, 313–315
Pythium spp., 317–318
S100A12, 322
small intestine function– and disease–related, 318–321

Chronic idiopathic large bowel diarrhea (CILBD), in dogs, 447–456
authors’ study of, 450–453
colonic motility and, 449
described, 447
practical relevance of, 453–454
published studies of, 449–450

Chronic inflammatory disease, in dogs and cats, ultrasonography of, 332–335
CILBD. See Chronic idiopathic large bowel diarrhea (CILBD).
Client education and compliance, in AFR management in dogs and cats, 375

Clostridium spp.
C. difficile, bacterial enteritis in dogs and cats due to, 291–294
described, 291
diagnosis of, 291–293
culture in, 292
ELISA in, 292
fecal toxin detection in, 292–293
molecular techniques in, 293
treatment of, 293
zoonotic implications, 294

C. perfringens, bacterial enteritis in dogs and cats due to, 294–297
described, 294–295
Clostridium (continued)
  diagnosis of, 295–296
  treatment of, 296
  zoonotic implications, 296–297
  diagnostic tests for, in dogs and cats, 316–317
Cobalamin deficiency
  in dogs and cats with CE, laboratory tests in assessment of, 318–319
  in SIBO diagnosis, 280
Colitis, granulomatous, in Boxer dogs, 433–445. See also Granulomatous colitis, in Boxer dogs.
Colonic motility, in dogs, 449
C-reactive protein (CRP) concentrations, assessment of, in dogs and cats with chronic enteropathies, 321
Crohn disease, AIEC in, in Boxer dogs, 437–438
CRP. See C-reactive protein (CRP).
Crypt cysts/abscesses, in dogs, treatment of, 394–395
Crypt disease, in dogs, 403
Cryptosporidium spp., detection of, in dogs and cats, 315
Cutaneous adverse food reactions (CAFRs), in dogs and cats, 366–368
Cyst(s), crypt, in dogs, treatment of, 394–395
Cytokine(s), inflammatory, as markers of intestinal disease in dogs and cats, 352–355.
  See also Inflammatory cytokines, as markers of intestinal disease in dogs and cats.

D
Diarrhea
  antibiotic-responsive, in small animals, 273–286. See also Antibiotic-responsive diarrhea (ARD), in small animals.
  ARD and, reasons for, 279
  chronic idiopathic large bowel, in dogs, 447–456. See also Chronic idiopathic large bowel diarrhea (CILBD), in dogs.
  SIBO and, reasons for, 279
Diet(s)
  as factor in IBD in dogs, 384
  hydrolyzed, in AFR management in dogs and cats, 374–375
  protein, novel, in AFR management in dogs and cats, 374
Dietary elimination trial, in AFR management in dogs and cats, 373–374
Dietary provocation test, in AFR management in dogs and cats, 375–376
Diet-responsive chronic enteropathy, in dogs and cats
  AFRs related to, 368–369
  pathogenesis of, 365
Dog(s)
  AFRs in, 361–379. See also Adverse food reactions (AFRs), in dogs and cats.
  alimentary lymphoma in, 430
  bacterial enteritis in, 287–309. See also Bacterial enteritis, in dogs and cats.
  Boxer, granulomatous colitis in, 433–445. See also Granulomatous colitis, in Boxer dogs.
  CEs in. See also Chronic enteropathy (CE), in dogs and cats.
  chronic enteropathies in, 311–328
  CILBD in, 447–456. See also Chronic idiopathic large bowel diarrhea (CILBD), in dogs.
  colonic motility in, 449
IBD in, 348–352, 381–398. See also Inflammatory bowel disease (IBD), in dogs.

intestinal microbiota of, 261–272. See also Intestinal microbiota, of dogs and cats.

intestine of, clinical immunoology and immunopathology of, 345–360. See also Intestine(s), of dogs and cats, clinical immunology and immunopathology of.

PLEs in, 399–418. See also Protein-losing enteropathies (PLEs), in dogs.

small intestinal inflammatory and neoplastic diseases in, ultrasonography of, 329–344.

See also Ultrasonography, of small intestinal inflammatory and neoplastic diseases, in dogs and cats.

Drug(s), in AFR management in dogs and cats, 375

E

ELISA. See Enzyme-linked immunosorbent assay (ELISA).

Enteritis

bacterial, in dogs and cats, 287–309. See also Bacterial enteritis, in dogs and cats.
eosinophil-predominant, in dogs, treatment of, 392–393

regional, in dogs, 403

Enteropathy(ies)

cellular. See Chronic enteropathy (CE).

granulomatous, in dogs, treatment of, 390–391

lymphocyte and plasma cell predominant, in dogs, treatment of, 391–392

minimal change, in dogs, treatment of, 389–390

neutrophilic, in dogs, treatment of, 390–391

protein-losing. See Protein-losing enteropathies (PLEs).

Enzyme-linked immunosorbent assay (ELISA), in detection of C. difficile–related bacterial enteritis in dogs and cats, 292

Eosinophil-predominant enteritis, in dogs, treatment of, 392–393

EPI. See Exocrine pancreatic insufficiency (EPI).

Escherichia coli

adherent and invasive, in Crohn disease, in Boxer dogs, 437–438

diagnostic tests for, in dogs and cats, 312

invasive, granulomatous colitis and, in Boxer dogs, 435–436

Exocrine pancreatic insufficiency (EPI), 312

F

Fecal α1-PI assay, in assessment of dogs and cats with chronic enteropathies, 320–321

Fecal examination, in helminths detection, 312–313

Fecal toxin detection, of C. difficile–related bacterial enteritis in dogs and cats, 292–293

Fingerprinting, molecular, in intestinal microbiome characterization, 263

FISH analysis. See Fluorescence in situ hybridization (FISH) analysis.

Fluorescence in situ hybridization (FISH) analysis, in granulomatous colitis diagnosis

in Boxer dogs, 439

Folate deficiency, in dogs and cat with CE, laboratory tests in assessment of, 319–320

Functional intestinal disorders, in humans, 448–449

Fungal organisms, in dogs and cats, 266–267

G

Gastrointestinal (GI) hemodynamics, in dogs and cats, ultrasonography of, 341

Gastrointestinal (GI) lesions, severity of, correlating clinical activity and histopathologic assessment of, challenges related to, 457–463
Gastrointestinal (GI) mucosal barrier, in pathogenesis of AFRs in dogs and cats, 362–363
Gastrointestinal (GI) neoplasia, in dogs, 404
Gastrointestinal (GI) tract, of dogs and cats, bacteria in
cultural results of, 265
detection of, molecular tools in, 265–266
Genetic(s)
granulomatous colitis in Boxer dogs related to, 436–437
IBD in dogs related to, 351–352, 381–383
GI. See Gastrointestinal (GI).
Giardia spp., in dogs and cats, detection of, 313–315
Gluten-sensitive enteropathy, in pathogenesis of AFRs in dogs and cats, 364–365
Granulomatous colitis, in Boxer dogs, 433–445
clinical features of, 438
described, 433–434
diagnosis of, 438–440
antimicrobial susceptibility testing in, 435–436
FISH analysis in, 439
future directions in, 440
traditional diagnostics in, 438–439
genetics in, 436–437
invasive Escherichia coli and, 435–436
recent discoveries, 435–438
treatment of, 440–442
Granulomatous enteropathy, in dogs, treatment of, 390–391
Gut-associated lymphoid tissue, of dogs and cats, clinical immunology and
immunopathology of, 345–348

H
Helminth(s), in dogs and cats, diagnostic tests for, 312–313
Heterobilharzia americana, in dogs and cats, detection of, 313
Histoplasma, in dogs and cats, diagnostic tests for, 317
Human(s)
functional intestinal disorders in, 448–449
IBS in, 448–449
PLEs in, causes of, 400
Hydrogen, breath, in SIBO diagnosis, 280
Hydrolyzed diets, in AFR management in dogs and cats, 374–375

I
IBD. See Inflammatory bowel disease (IBD).
IBS. See Irritable bowel syndrome (IBS).
Idiopathic ARD, diagnosis of, 282
Idiopathic SIBO, existence of, 277–278
IgA. See Immunoglobulin A (IgA).
Immunoglobulin A (IgA)
mucosal, production of, in dog and cat intestine, 345–346
production of
in isolated lymphoid follicles and lamina propria, 346–347
in Peyer patches, in dog and cat intestine, 346
Immunology, clinical, of dog and cat intestine, 345–360. See also Intestine(s), of dogs and cats, clinical immunology and immunopathology of.

Immunopathology, clinical, of dog and cat intestine, 345–360. See also Intestine(s), of dogs and cats, clinical immunology and immunopathology of.

Infection(s), bacterial, diagnostic tests for, in dogs and cats, 316–317

Infectious diseases
of small intestine, in dogs and cats, ultrasonography of, 335–336
PLEs-related, in dogs, 404

Inflammatory bowel disease (IBD)
described, 381
in dogs, 381–398
bacteria and, 383–384
diagnosis of, 384–386
dietary constituents in, 384
dysbalance of intestinal microbiota and, 351
genetic predisposition to, 351–352
genetic susceptibility of, 381–383
histopathologic evaluation of, 387–389
immunologic markers of, 352
innate immunity hyperreactivity in intestine and, 349–351
intestinal biopsy for, 386
intestinal microenvironment of, 383–384
pathogenesis of, 348–352
interplay of mucosal innate immunity with intestinal microbiota, 348–352
treatment of, 389
crypt cysts/abscesses, 394–395
eosinophil-predominant enteritis, 392–393
granulomatous or neutrophilic enteropathy, 390–391
lymphangiectasia, 394–395
lymphocyte and plasma cell predominant enteropathy, 391–392
minimal change enteropathy, 389–390

Inflammatory cytokines, as markers of intestinal disease in dogs and cats, 352–355
pANCAs, 353–354
PARR, 354–355
P-glycoprotein, 352–353

Inflammatory disease(s), chronic, in dogs and cats, ultrasonography of, 332–335

Innate immunity hyperreactivity, in intestine of dogs with IBD, 349–351

Intestinal bacteria, of dogs and cats, 261–266
characterization of, methods for, 261–266. See also Intestinal microbiota, of dogs and cats, characterization of, methods for.

Intestinal biopsy
in IBD diagnosis in dogs, 386
in PLE diagnosis in dogs, 407

Intestinal disorders, functional, in humans, 448–449

Intestinal lesions, PLE-related, in dogs, treatment of, 412

Intestinal microbiota
mucosal innate immunity and, IBD in dogs and, 348–352
of dogs, with IBD, dysbalance of, 351
of dogs and cats, 261–272
archaea, 267–269
characterization of, methods for, 261–266
Intestinal (continued)
  bacterial culture, 261, 263–265
  molecular fingerprinting, 263
  molecular tools, 263–265
  fungal organisms, 266–267
  intestinal bacteria, 261–266. See also Intestinal bacteria, of dogs and cats.
  viruses, 269
Intestinal neoplasia, in dogs and cats, ultrasonography of, 336–338
Intestinal permeability, in SIBO diagnosis, 281
Intestine(s)
  microenvironment of, IBD in dogs related to, 383–384
  of dogs, with IBD, innate immunity hyperreactivity in, 349–351
  of dogs and cats, clinical immunology and immunopathology of, 345–360
    gut-associated lymphoid tissue, 345–348
    IBD, 348–352
    immunologic markers of, 352
    inflammatory cytokine measurement as marker of disease, 352–355
Irritable bowel syndrome (IBS), in humans, 448–449

L
Lamina propria, IgA production in, in dog and cat intestine, 346–347
Lesion(s)
  gastrointestinal, severity of, correlating clinical activity and histopathologic
    assessment of, challenges related to, 457–463
  intestinal, PLE-related, in dogs, treatment of, 412
Lymphadenopathy, regional, in dogs and cats, ultrasonography of, 339
Lymphangiectasia, in dogs, 400–401
  treatment of, 394–395
Lymphocyte and plasma cell predominant enteropathy, in dogs, treatment of, 391–392
Lymphoid follicles, isolated, IgA production in, in dog and cat intestine, 346–347
Lymphoid tissue, gut-associated, of dogs and cats, clinical immunology and
  immunopathology of, 345–348
Lymphoma(s), alimentary, in cats, 419–429. See also Alimentary lymphoma, in cats.

M
Metagenomics, in intestinal microbiome characterization, 264–265
N-Methylhistamine, in GI diagnosis, 323
Microbiota, intestinal. See Intestinal microbiota.
Minimal change enteropathy, in dogs, treatment of, 389–390
Molecular diagnostic testing, for Campylobacter spp.–related bacterial enteritis in dogs
  and cats, 290
Molecular fingerprinting, in intestinal microbiome characterization, 263
Molecular tools, in intestinal microbiome characterization, 263–265
  identification of bacterial groups, 263
  limitations of, 264
  metagenomics, 264–265
  molecular fingerprinting, 263
  quantification of bacterial groups, 264
  transcriptomics, 264–265
Motility disorders, in dogs and cats, ultrasonography of, 340–341
Mucosal innate immunity, intestinal microbiota and, IBD in dogs and, 348–352

N
Neoplasia(s)
GI, in dogs, 404
intestinal, in dogs and cats, ultrasonography of, 336–338
Neutrophilic enteropathy, in dogs, treatment of, 390–391
Nutritional support, in PLE management in dogs, 409, 411

O
Oncotic support, in PLE management in dogs, 411
Oral medications, in AFR management in dogs and cats, 375
Oral tolerance, in dogs and cats
in pathogenesis of AFRs, 363
intestinal immunology and immunopathology related to, 347–348

P
pANCAs. See Perinuclear antineutrophilic cytoplasmic antibodies (pANCAs).
Parasitism, in dogs, 404
PARR. See Polymerase chain reaction for antigen receptor rearrangements (PARR).
Perinuclear antineutrophilic cytoplasmic antibodies (pANCAs)
as marker of intestinal disease in dogs and cats, 353–354
in GI disease diagnosis, 322
Peyer patches, IgA production in, in dog and cat intestine, 346
P-glycoprotein, as marker of intestinal disease in dogs and cats, 352–353
PLEs. See Protein-losing enteropathies (PLEs).
Polymerase chain reaction for antigen receptor rearrangements (PARR), as markers
of intestinal disease in dogs and cats, 354–355
Protein diets, novel, in AFR management in dogs and cats, 374
Protein-losing enteropathies (PLEs)
described, 399
in cats, 311
in dogs, 311, 399–418
classification of, 399–404
clinical presentation of, 404
clinical scoring for, 410
complications of, 405
crypt disease, 403
diagnosis of, 405–408
histopathologic evaluation in, 407–408
imaging in, 406–407
in identification of origin of protein loss, 405–406
small intestinal biopsies in, 407
GI neoplasia, 404
IBD, 401–403. See also Inflammatory bowel disease (IBD).
infectious diseases associated with, 404
intestinal lesions due to, treatment of, 412
Protein-losing (continued)
   lymphangiectasia, 400–401
   parasitism, 404
   prognosis of, 408–409
   regional enteritis, 403
   treatment of, 409–412
      complications related to, 411–412
      nutritional support in, 409, 411
      oncotic support in, 411
   in humans, causes of, 400
Protozoal infections, diagnostic tests for, in dogs and cats, 313–315
   Cryptosporidium spp., 315
   Giardia spp., 313–315
   Tritrichomonas foetus, 315
Pythium spp., diagnostic tests for, in dogs and cats, 317–318

R
Regional enteritis, in dogs, 403
Regional lymphadenopathy, in dogs and cats, ultrasonography of, 339

S
S100A12, in GI disease diagnosis, 322
Salmonella spp., bacterial enteritis in dogs and cats due to, 297–299
   described, 297
   diagnosis of, 297–298
   treatment of, 298
   zoonotic implications, 299
Serum folate, in SIBO diagnosis, 280
SIBO. See Small intestinal bacterial overgrowth (SIBO).
Small intestinal bacterial overgrowth (SIBO), 273
   described, 274
   diagnosis of, 280–282
      bacterial metabolism markers in, 282
      breath hydrogen in, 280
      intestinal permeability in, 281
      lack of histopathologic changes on intestinal biopsy in, 282
      serum folate and cobalamin in, 280
      unconjugated bile salts in, 280
   existence of, 277
   idiopathic, existence of, 277–278
Small intestine
   bacteria in, numbers of, 274–277
   chronic enteropathies effects on, in dogs and cats, laboratory tests in assessment of, 318–321
   inflammatory and neoplastic diseases of, in dogs and cats, ultrasonography of, 329–344. See also Ultrasonography, of small intestinal inflammatory and neoplastic diseases, in dogs and cats.
   ultrasonography of, examination technique, 330–332
T
Transcriptomics, in intestinal microbiome characterization, 264–265
*Tritrichomonas foetus*, detection of, in dogs and cats, 315

U
Ultrasonography, of small intestinal inflammatory and neoplastic diseases, in dogs and cats, 329–344
chronic inflammatory disease, 332–335
complications related to, 342
described, 329
equipment for, 330
examination technique, 330–332
gastrointestinal hemodynamics, 341
infectious diseases, 335–336
intestinal neoplasia, 336–338
motility disorders, 340–341
regional lymphadenopathy, 339

V
Virus(es), in dogs and cats, 269